Advisor Group Holdings, Inc. Corvus Pharmaceuticals, Inc. Transaction History
Advisor Group Holdings, Inc.
- $52.6 Billion
- Q2 2025
A detailed history of Advisor Group Holdings, Inc. transactions in Corvus Pharmaceuticals, Inc. stock. As of the latest transaction made, Advisor Group Holdings, Inc. holds 67,322 shares of CRVS stock, worth $514,340. This represents 0.0% of its overall portfolio holdings.
Number of Shares
67,322
Previous 67,989
0.98%
Holding current value
$514,340
Previous $271,000
0.74%
% of portfolio
0.0%
Previous 0.0%
Shares
10 transactions
Others Institutions Holding CRVS
# of Institutions
105Shares Held
38.9MCall Options Held
98.5KPut Options Held
226K-
Orbimed Advisors LLC San Diego, CA7.17MShares$54.7 Million1.02% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct7.04MShares$53.8 Million0.06% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.28MShares$25.1 Million0.0% of portfolio
-
Adams Street Partners LLC Chicago, IL3.28MShares$25 Million9.69% of portfolio
-
Rtw Investments, LP New York, NY2.68MShares$20.5 Million0.16% of portfolio
About Corvus Pharmaceuticals, Inc.
- Ticker CRVS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 46,553,500
- Market Cap $356M
- Description
- Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase Ib/II clinical trial for non-small cell lung cancer and head and neck cancers. The compan...